Physician profile
Vahe Matnishian
NPI 1144843111
$3,075.28
in general payments reported to CMS, 2019-2025
13 companies · $1,699 in 2025
The $1,699 reported for 2025 was more than what 93% of Primary Podiatric Medicine providers received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $558 · 2024: $818 · 2025: $1,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,872 · Travel and Lodging: $1,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,872.09 |
| Travel and Lodging | $1,203.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $1,941.66 | 2024-2025 | |
| Stryker Corporation | $207.13 | 2023-2025 | Prostep, Variax, Citrefix |
| Mission Medical Distribution, LLC | $201.31 | 2023-2024 | |
| Sanara Medtech INC. | $192.35 | 2024 | Celleraterx |
| Abbott Laboratories | $142.03 | 2024 | Diamondback Peripheral |
| Orthofix Medical, INC. | $121.82 | 2023 | Truelok, Trinity Elite, Truelok System |
| Seapearl East, INC | $113.66 | 2023 | |
| Southern Edge Orthopaedics, INC. | $50.49 | 2024 | |
| Depuy Synthes Sales INC. | $35.33 | 2025 | Motoband |
| Solventum Corporation | $24.02 | 2025 | Activ.A.C. |
| Bioventus LLC | $17.27 | 2025 | Exogen Ultrasound Bone Healing System |
| Smith+Nephew, INC. | $14.95 | 2024 | Regranex, Collagenase Santyl |
| Paratek Pharmaceuticals, INC. | $13.26 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vahe Matnishian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.